International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
Conditions: Leukemia
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT03007147.
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Conditions: Leukemia
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Conditions: Leukemia
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT03817398.
A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Conditions: Leukemia
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT04293562.
An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation
Conditions: Leukemia
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT04203316.
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
Conditions: Leukemia
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT04726241.
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Conditions: Medulloblastoma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT02724579.
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG)
Conditions: Glioma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Conditions: Glioma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Conditions: Glioma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Conditions: Central Nervous System Tumors
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Conditions: Central Nervous System Tumors
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT04684368.
A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features
Conditions: Medulloblastoma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05382338.
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Conditions: Sarcoma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05235165.
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Conditions: Sarcoma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05691478.
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
Conditions: Sarcoma
Principal Investigator: Maggie Fader
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT04994132.
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Conditions: Sarcoma
Principal Investigator: Maggie Fader
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05304585.
A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Conditions: Germ Cell Tumor
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT03067181.
Phase 3 Accelerated BEP Trial: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumors
Conditions: Germ Cell Tumor
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
Conditions: Neuroblastoma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT03126916.
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Conditions: Neuroblastoma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT03794349.
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) – Phase 2/3
Conditions: Hepatic Malignancy
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Conditions: Hodgkin's Lymphoma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05675410.
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Conditions: Wilms Tumor
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT04322318.
Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer
Conditions: Childhood Cancer
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05228275.
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
Conditions: Langerhans Cell Histiocytosis
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05828069.
A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms
Conditions: B-Cell Neioplasms
Principal Investigator: Maggie Fader
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05206357.
Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Either Single Cycle (Low-Risk Patients) Or Randomization (High Risk Patients) To Either Single-Cycle Or To Three Tandem Cycles Of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
Conditions: Medulloblastoma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants with Progressive NF2 Mutated Meningiomas
Conditions: Meningioma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05130866.
A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma
Conditions: Neuroblastoma
Principal Investigator: Guillermo De Angulo
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT02559778.
A Randomized, Open-Label, Active Controlled, Safety And Descriptive Efficacy Study In Pediatric Subjects Requiring Anticoagulation For The Treatment Of A Venous Thromboembolic Event
Conditions: Venous Thromboembolic Event
Principal Investigator: Maggie Fader
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT02464969.
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
Conditions: Diffuse Midline Glioma
Principal Investigator: Ossama Maher
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05518838.